Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancer

 Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancer

Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancer

Shots:

  • The approval is based on REFLECTIONS B327-02 study assessing Trazimera in 500 patients with HER2 overexpressing breast cancer & m- gastric/GEJ adenocarcinoma across 20 countries
  • REFLECTIONS B327-02 study demonstrated a high degree of similarity & no clinical differences b/w Trazimera & Herceptin
  • Trazimera (trastuzumab-biosimilar) is a HER2 receptor antagonist biosimilar to Herceptin and has received EU’s approval in Jul’18 for the same indication

Click here to read full press release/ article | Ref: Pfizer | Image: Pfizer Centreone

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post